{"title":"Enhancing the therapeutic efficacy of piperine in colorectal cancer: development and evaluation of piperine-loaded PLGA-b-PEG copolymer nanoparticles","authors":"Nuttapol Risangud , Nisachon Jangpromma , Phraepakaporn Kunnaja , Natthakarn Chiranthanut , Sakda Daduang , Kantapat Chansaenpak , Ruedeemars Yubolphan","doi":"10.1016/j.ejpb.2025.114796","DOIUrl":null,"url":null,"abstract":"<div><div>Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related morbidity and mortality worldwide. Piperine, a natural alkaloid from <em>Piper nigrum L</em>. and <em>Piper longum L.</em>, has shown potential anti-cancer properties, including the ability to induce apoptosis and inhibit cell cycle progression. However, its clinical application is limited by low solubility and poor bioavailability. In this study, we developed piperine-encapsulated PLGA-<em>b</em>-PEG nanoparticles (Pip-PLNP) using a nanoprecipitation method, which achieved a favorable hydrodynamic diameter of approximately 43.8 ± 0.4 nm to 49.1 ± 0.2 nm and high encapsulation efficiency (∼80 %) in a stable, monodisperse form. The anti-cancer effects of Pip-PLNP were evaluated in HCT116 human colorectal carcinoma cells. MTT assays revealed that Pip-PLNP exhibited significant dose- and time-dependent cytotoxicity, with improved potency compared to free piperine. Apoptosis assays demonstrated that Pip-PLNP induced early and late apoptosis more effectively than free piperine. Additionally, cell cycle analysis showed that Pip-PLNP caused G0/G1 phase arrest, consistent with piperine’s known mechanism of action. In conclusion, Pip-PLNP significantly enhances the anti-cancer efficacy of piperine by improving its bioavailability, cytotoxicity, and apoptotic activity, suggesting its potential as a therapeutic approach for colorectal cancer treatment.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"214 ","pages":"Article 114796"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125001730","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related morbidity and mortality worldwide. Piperine, a natural alkaloid from Piper nigrum L. and Piper longum L., has shown potential anti-cancer properties, including the ability to induce apoptosis and inhibit cell cycle progression. However, its clinical application is limited by low solubility and poor bioavailability. In this study, we developed piperine-encapsulated PLGA-b-PEG nanoparticles (Pip-PLNP) using a nanoprecipitation method, which achieved a favorable hydrodynamic diameter of approximately 43.8 ± 0.4 nm to 49.1 ± 0.2 nm and high encapsulation efficiency (∼80 %) in a stable, monodisperse form. The anti-cancer effects of Pip-PLNP were evaluated in HCT116 human colorectal carcinoma cells. MTT assays revealed that Pip-PLNP exhibited significant dose- and time-dependent cytotoxicity, with improved potency compared to free piperine. Apoptosis assays demonstrated that Pip-PLNP induced early and late apoptosis more effectively than free piperine. Additionally, cell cycle analysis showed that Pip-PLNP caused G0/G1 phase arrest, consistent with piperine’s known mechanism of action. In conclusion, Pip-PLNP significantly enhances the anti-cancer efficacy of piperine by improving its bioavailability, cytotoxicity, and apoptotic activity, suggesting its potential as a therapeutic approach for colorectal cancer treatment.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.